GLP-1 receptor agonists produce 15–20% weight loss and reduce major cardiovascular events by 20% in people with obesity.
20% MACE reductionThe SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in people with obesity without diabetes
What the researchers found
GLP-1 receptor agonists work by mimicking the natural gut hormone GLP-1, which reduces appetite and slows stomach emptying. Semaglutide and liraglutide are the two GLP-1 drugs FDA-approved for weight management.
Beyond weight loss, these drugs show early evidence of cardiovascular benefits in obese patients, including reduced cardiovascular events and improved risk factors. The SELECT trial showed semaglutide reduced major cardiovascular events by 20% in obese people without diabetes.
Common side effects are gastrointestinal (nausea, vomiting, diarrhea) and are usually mild to moderate. The review discusses strategies for managing these effects, including gradual dose escalation.
Why it matters
Diet and exercise alone produce modest long-term weight loss. GLP-1 drugs have changed the treatment landscape by producing 15-20% weight loss in clinical trials. The additional cardiovascular benefits make them potentially life-saving, not just cosmetic, treatments for obesity.
The numbers in context
- Semaglutide and liraglutide: both FDA-approved for weight loss
- GLP-1 drugs: significant and sustained weight loss in trials
- SELECT trial: 20% reduction in major cardiovascular events with semaglutide in obesity
- Common side effects: nausea, vomiting, diarrhea (usually mild-moderate)
How the study worked
Narrative review of published literature covering GLP-1 receptor agonist mechanisms, clinical trial results for weight loss, cardiovascular outcome data, adverse effects, and side effect management strategies.
Who was studied
Review of GLP-1 receptor agonist evidence in obese populations
What this study cannot tell us
This is a narrative review without systematic methodology or meta-analysis. It does not cover tirzepatide or newer multi-agonists. The cardiovascular outcome data for obesity (as opposed to diabetes) is limited to the SELECT trial for semaglutide. Long-term effects beyond 2-3 years are unknown. Weight regain after stopping the drugs is not thoroughly addressed.
How to read the evidence
Rated strong: review draws on large phase 3 trials and the landmark SELECT cardiovascular outcomes trial.
When this study was published
Published in 2024. Includes SELECT trial results, which represent the most current cardiovascular data for GLP-1 drugs in obesity.
The bigger picture
Diet and exercise alone produce modest long-term weight loss. GLP-1 drugs have changed the treatment landscape, and the additional cardiovascular protection makes them the most complete obesity pharmacotherapy available.
Questions still open
- How long do patients need to stay on GLP-1 drugs to maintain weight loss?
- Will insurance coverage expand as cardiovascular benefits become clearer?
Common questions
How much weight can GLP-1 drugs help you lose?
Do GLP-1 drugs prevent heart attacks?
Read the original research
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.
Medicine, 103(44), e40364
Citation
Raza, Fatima Ali; Altaf, Rafiya; Bashir, Talha; Asghar, Fatima; Altaf, Rabiya; Tousif, Sohaib; Goyal, Aman; Mohammed, Aisha; Mohammad, Mahnoor Faisal; Anan, Mahfuza; Ali, Sajjad. (2024). Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.. Medicine, 103(44), e40364. https://doi.org/10.1097/MD.0000000000040364